Potential biomarkers of major depression diagnosis and chronicity

dc.contributor.authorGalvão, Ana Cecília de Menezes
dc.contributor.authorAlmeida, Raissa Nobrega
dc.contributor.authorSousa Júnior, Geovan Menezes de
dc.contributor.authorLeocadio-Miguel, Mário André
dc.contributor.authorFontes, Fernanda Palhano Xavier de
dc.contributor.authorAraujo, Draulio Barros de
dc.contributor.authorLobão-Soares, Bruno
dc.contributor.authorMaia-de-Oliveira, João Paulo
dc.contributor.authorNunes, Emerson Arcoverde
dc.contributor.authorHallak, Jaime Eduardo Cecilio
dc.contributor.authorSarris, Jerome
dc.contributor.authorGalvão-Coelho, Nicole Leite
dc.date.accessioned2021-11-30T14:21:34Z
dc.date.available2021-11-30T14:21:34Z
dc.date.issued2021-09-29
dc.description.resumoMolecular biomarkers are promising tools to be routinely used in clinical psychiatry. Among psychiatric diseases, major depression disorder (MDD) has gotten attention due to its growing prevalence and morbidity. We tested some peripheral molecular parameters such as serum mature Brain-Derived Neurotrophic Factor (mBDNF), plasma C-Reactive Protein (CRP), serum cortisol (SC), and the salivary Cortisol Awakening Response (CAR), as well as the Pittsburgh sleep quality inventory (PSQI), as part of a multibiomarker panel for potential use in MDD diagnosis and evaluation of disease’s chronicity using regression models, and ROC curve. For diagnosis model, two groups were analyzed: patients in the first episode of major depression (MD: n = 30) and a healthy control (CG: n = 32). None of those diagnosis models tested had greater power than Hamilton Depression Rating Scale-6. For MDD chronicity, a group of patients with treatment-resistant major depression (TRD: n = 28) was tested across the MD group. The best chronicity model (p < 0.05) that discriminated between MD and TRD included four parameters, namely PSQI, CAR, SC, and mBDNF (AUC ROC = 0.99), with 96% of sensitivity and 93% of specificity. These results indicate that changes in specific biomarkers (CAR, SC, mBDNF and PSQI) have potential on the evaluation of MDD chronicity, but not for its diagnosis. Therefore, these findings can contribute for further studies aiming the development of a stronger model to be commercially available and used in psychiatry clinical practicept_BR
dc.identifier.citationGALVÃO, Ana Cecília de Menezes; ALMEIDA, Raíssa Nobrega; SOUSA JÚNIOR, Geovan Menezes de; LEOCADIO-MIGUEL, Mário André; PALHANO-FONTES, Fernanda; ARAUJO, Dráulio Barros de; LOBÃO-SOARES, Bruno; MAIA-DE-OLIVEIRA, João Paulo; NUNES, Emerson Arcoverde; HALLAK, Jaime Eduardo Cecilio; SARRIS,Jerome; GALVÃO-COELHOI,Nicole Leite. Potential biomarkers of major depression diagnosis and chronicity. Plos One, [S. l.], v. 16, n. 9, p. 1-17, 29 set. 2021. Doi: 10.1371/journal.pone.0257251pt_BR
dc.identifier.doi10.1371/journal.pone.0257251
dc.identifier.urihttps://repositorio.ufrn.br/handle/123456789/45096
dc.languageenpt_BR
dc.rightsAttribution 3.0 Brazil*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/br/*
dc.subjectDepressionpt_BR
dc.subjectMajor depression disorder (MDD)pt_BR
dc.subjectMolecular biomarkerspt_BR
dc.subjectpsychiatric diseasespt_BR
dc.titlePotential biomarkers of major depression diagnosis and chronicitypt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
PotentialBiomarkersDepression_Araujo_2021.pdf
Tamanho:
886.6 KB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.45 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar